Research Progress on Psychotropic Medications and Sexual Dysfunction

doi:10.12114/j.issn.1007-9572.2018.00.453

Abstract

Abstract: Patients with psychiatric illness are often troubled by sexual dysfunction and many sexual symptoms resolve as the mental state improves.However，treatment-emergent sexual adverse events tend to persist over time，such as decreased libido，delayed orgasm，and sexual arousal difficulties caused by antidepressants，antipsychotics and mood stabilizers，which is usually ignored by clinicians due to cultural or professional factors.Treatment-emergent sexual dysfunction adversely affects quality of life and may contribute to reducing treatment adherence.Thus，this study is designed to report the treatment effect of three psychosis（schizophrenia，depression and bipolar disorder）on sexual dysfunction，and the management of sexual dysfunction，providing psychiatrists some suggestions about optimal protocol of psychotropic treatment.

Key words: Psychotic disorders, Schizophrenia, Depressive disorder, Bipolar disorder, Antipsychotic agents, Sexual dysfunctions, Quality of life

摘要： 精神疾病患者常伴随性功能障碍（SD），很多患者SD会随着精神疾病的好转而好转，但由抗精神病药物引起的症状却会一直存在，如服用抗抑郁症药物、抗精神分裂症药物以及情绪稳定剂引起的性欲减退、高潮障碍、唤起障碍等。由于文化因素以及专业性等问题，精神疾病患者治疗期间出现的SD常被临床医生所忽视，但SD会严重影响患者的生活质量并降低患者的用药依从性。因此，本文通过搜索国内外相关文献，重点介绍3种常见精神疾病（精神分裂症、抑郁症、双相障碍）的治疗对SD的影响，以期为精神疾病的临床治疗提供建议和参考。

关键词: 精神病, 精神分裂症, 抑郁症, 双相情感障碍, 抗精神病药, 性功能障碍, 生活质量

YE Zengjie,LIANG Muzi. Research Progress on Psychotropic Medications and Sexual Dysfunction　[J]. Chinese General Practice, 2019, 22(15): 1884-1888. DOI: 10.12114/j.issn.1007-9572.2018.00.453.
叶增杰,梁木子. 抗精神病药物与性功能障碍关系研究进展[J]. 中国全科医学, 2019, 22(15): 1884-1888. DOI: 10.12114/j.issn.1007-9572.2018.00.453.

References

［1］QUINN C，HAPPELL B.Talking about sexuality with consumers of mental health services［J］．Perspect Psychiatr Care，2013，49（1）：13-20．DOI：10.1111/j.1744-6163.2012.00334.x.
［2］SIMIYON M，CHANDRA P S，DESAI G.Sexual dysfunction among women with Schizophrenia——a cross sectional study from India［J］．Asian J Psychiatry，2016，24：93-98．DOI：10.1016/j.ajp.2016.08.022.
［3］ADAM R L，SIDI H，MIDIN M，et al．The role of atypical antipsychotics in sexuality：road to recovery in schizophrenia［J］．Curr Drug Targets，2018，19（12）：1402-1411．DOI：10.2174/1389450118666170502130126.
［4］DE JAGER J，MCCANN E.Psychosis as a barrier to the expression of sexuality and intimacy：an environmental risk?［J］．Schizophr Bull，2017．［Epub ahead of print］．DOI：10.1093/schbul/sbw172.
［5］HOU C L，ZANG Y，ROSEN R C，et al．Sexual dysfunction and its impact on quality of life in Chinese patients with schizophrenia treated in primary care［J］．Compr Psychiatry，2016，65：116-121．DOI：10.1016/j.comppsych.2015.11.002.
［6］MONTEJO A L，MAJADAS S，MONTEJO-EGIDO L.EPA-1591-Sexual and relational dysfunctions in people wit schizophrenia［J］．Eur Psychiatry，2014，29（1）：1．DOI：10.1016/S0924-9338（14）78746-2.
［7］GONZALEZ-TORRES M A，SALAZAR M A，INCHAUSTI L，et al．Lifetime sexual behavior of psychiatric inpatients［J］．J Sex Med，2010，7（9）：3045-3056．DOI：10.1111/j.1743-6109.2010.01795.x.
［8］KELLY D L，CONLEY R R.Sexuality and schizophrenia：a review［J］．Schizophr Bull，2004，30（4）：767-779.
［9］BOBES J，GARCIA-PORTILLA M P，REJAS J，et al．Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone，olanzapine，quetiapine，or haloperidol：the results of the EIRE study［J］．J Sex Marital Ther，2003，29（2）：125-147.
［10］MALIK P，KEMMLER G，HUMMER M，et al．Sexual dysfunction in first-episode schizophrenia patients：results from European First Episode Schizophrenia Trial［J］．J Clin Psychopharmacol，2011，31（3）：274-280．DOI：10.1097/JCP.0b013e3182199bcc.
［11］WEIDEN P J，MILLER A L.Which side effects really matter? Screening for common and distressing side effects of antipsychotic medications［J］．J Psychiatr Pract，2001，7（1）：41-47.
［12］SERRETTI A，CHIESA A.A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics［J］．Int Clin Psychopharmacol，2011，26（3）：130-140．DOI：10.1097/yic.0b013e328341e434.
［13］MONTES DE OCA P，MACOTELA Y，NAVA G，et al．Prolactin stimulates integrin-mediated adhesion of circulating mononuclear cells to endothelial cells［J］．Lab Invest，2005，85（5）：633-642．DOI：10.1038/labinvest.3700256.
［14］MOLINARI C，GROSSINI E，MARY D A，et al．Prolactin induces regional vasoconstriction through the beta2-adrenergic and nitric oxide mechanisms［J］．Endocrinology，2007，148（8）：4080-4090．DOI：10.1210/en.2006-1577.
［15］DE HERT M，DETRAUX J，PEUSKENS J.Second-generation and newly approved antipsychotics，serum prolactin levels and sexual dysfunctions：a critical literature review［J］．Expert Opin Drug Saf，2014，13（5）：605-624．DOI：10.1517/14740338.2014.906579.
［16］DE BOER M K，CASTELEIN S，WIERSMA D，et al．A systematic review of instruments to measure sexual functioning in patients using antipsychotics［J］．J Sex Res，2014，51（4）：383-389．DOI：10.1080/00224499.2013.865111.
［17］DIBONAVENTURA M，GABRIEL S，DUPCLAY L，et al．A patient perspective of the impact of medication side effects on adherence：results of a cross-sectional nationwide survey of patients with schizophrenia［J］．BMC Psychiatry，2012，12：20．DOI：10.1186/1471-244X-12-20.
［18］THAROOR H，KALIAPPAN A，GOPAL S.Sexual dysfunctions in schizophrenia：professionals and patients perspectives［J］．Indian J Psychiatry，2015，57（1）：85-87．DOI：10.4103/0019-5545.148532.
［19］JEONG H G，LEE M S，LEE H Y，et al．Changes in sexual function and gonadal axis hormones after switching to aripiprazole in male schizophrenia patients：a prospective pilot study［J］．Int Clin Psychopharmacol，2012，27（4）：177-183．DOI：10.1097/YIC.0b013e328351c8c4.
［20］MENG M，LI W，ZHANG S，et al．Using aripiprazole to reduce antipsychotic-induced hyperprolactinemia：meta-analysis of currently available randomized controlled trials［J］．Shanghai Arch Psychiatry，2015，27（1）：4-17．DOI：10.11919/j.issn.1002-0829.215014.
［21］FUJIOI J，IWAMOTO K，BANNO M，et al．Effect of adjunctive aripiprazole on sexual dysfunction in schizophrenia：a preliminary open-label study［J］．Pharmacopsychiatry，2017，50（2）：74-78．DOI：10.1055/s-0042-116323.
［22］SCHMIDT H M，HAGEN M，KRISTON L，et al．Management of sexual dysfunction due to antipsychotic drug therapy［J］．Cochrane Database Syst Rev，2012，11：CD003546．DOI：10.1002/14651858.CD003546.pub3.
［23］MONTEJO á L，ARANGO C，BERNARDO M，et al．Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics［J］．Front Neuroendocrinol，2017，45：25-34．DOI：10.1016/j.yfrne.2017.02.003.
［24］ATLANTIS E，SULLIVAN T.Bidirectional association between depression and sexual dysfunction：a systematic review and meta-analysis［J］．J Sex Med，2012，9（6）：1497-1507．DOI：10.1111/j.1743-6109.2012.02709.x.
［25］ANGST J.Sexual problems in healthy and depressed persons［J］．Int Clin Psychopharmacol，1998，13 Suppl：S1-4.
［26］HEGEMAN J M，KOK R M，VAN DER MAST R C，et al．Phenomenology of depression in older compared with younger adults：meta-analysis［J］．Br J Psychiatry，2012，200（4）：275-281．DOI：10.1192/bjp.bp.111.095950.
［27］LAURENT S M，SIMONS A D.Sexual dysfunction in depression and anxiety：conceptualizing sexual dysfunction as part of an internalizing dimension［J］．Clin Psychol Rev，2009，29（7）：573-585．DOI：10.1016/j.cpr.2009.06.007.
［28］VULINK N C，DENYS D，BUS L，et al．Sexual pleasure in women with obsessive-compulsive disorder?［J］．J Affect Disord，2006，91（1）：19-25．DOI：10.1016/j.jad.2005.12.006.
［29］WILLIAMS K，REYNOLDS M F.Sexual dysfunction in major depression［J］．CNS Spectr，2006，11（8 Suppl 9）：19-23.
［30］KENNEDY S H，RIZVI S J，FULTON K，et al．The sex effects scale：pilot validation in a healthy population［J］．Psychopharmacol Bull，2010，43（3）：15-25.
［31］WILLIAMS V S，BALDWIN D S，HOGUE S L，et al．Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries：a cross-sectional patient survey［J］．J Clin Psychiatry，2006，67（2）：204-210.
［32］WILLIAMS V S，EDIN H M，HOGUE S L，et al．Prevalence and impact of antidepressant-associated sexual dysfunction in three European countries：replication in a cross-sectional patient survey［J］．J Psychopharmacol，2010，24（4）：489-496．DOI：10.1177/0269881109102779.
［33］GARTLEHNER G，HANSEN R A，MORGAN L C，et al．Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder：an updated meta-analysis［J］．Ann Intern Med，2011，155（11）：772-785．DOI：10.7326/0003-4819-155-11-201112060-00009.
［34］WATANABE N，OMORI I M，NAKAGAWA A，et al．Mirtazapine versus other antidepressive agents for depression［J］．Cochrane Database Syst Rev，2011（12）：CD006528．DOI：10.1002/14651858.CD006528.pub2.
［35］HICKIE I B，ROGERS N L.Novel melatonin-based therapies：potential advances in the treatment of major depression［J］．Lancet，2011，378（9791）：621-631．DOI：10.1016/S0140-6736（11）60095-0.
［36］CITROME L.Vilazodone for major depressive disorder：a systematic review of the efficacy and safety profile for this newly approved antidepressant——what is the number needed to treat，number needed to harm and likelihood to be helped or harmed?［J］．Int J Clin Pract，2012，66（4）：356-368．DOI：10.1111/j.1742-1241.2011.02885.x.
［37］BALDWIN D，HANUMANTHAIAH V B.Vortioxetine in the treatment of major depressive disorder［J］．Future Neurol，2015，10（2）：79-89．DOI：10.2217/fnl.14.69.
［38］ZOURKOVá A，SLANAR O，JARKOVSKY J，et al．MDR1 in paroxetine-induced sexual dysfunction［J］．J Sex Marital Ther，2013，39（1）：71-78．DOI：10.1080/0092623X.2012.668514.
［39］GIULIANO F，HELLSTROM W J G.The pharmacological treatment of premature ejaculation［J］．BJU Int，2008，102（6）：668-675．DOI：10.1111/j.1464-410x.2008.07719.x.
［40］FINK H A，MACDONALD R，RUTKS I R，et al．Trazodone for erectile dysfunction：a systematic review and meta-analysis［J］．BJU Int，2003，92（4）：441-446．DOI：10.1046/j.1464-410X.2003.04358.x.
［41］BALON R，SEGRAVES R T.Survey of treatment practices for sexual dysfunction（s）associated with anti-depressants［J］．J Sex Marital Ther，2008，34（4）：353-365．DOI：10.1080/00926230802096390.
［42］ROTHSCHILD A J.Selective serotonin reuptake inhibitor-induced sexual dysfunction：efficacy of a drug holiday［J］．Am J Psychiatry，1995，152（10）：1514-1516．DOI：10.1176/ajp.152.10.1514.
［43］FAVA M，DORDING C M，BAKER R A，et al．Effects of adjunctive aripiprazole on sexual functioning in patients with major depressive disorder and an inadequate response to standard antidepressant monotherapy：a post hoc analysis of 3 randomized，double-blind，placebo-controlled studies［J］．Prim Care Companion CNS Disord，2011，13（1）：PCC.10m00994．DOI：10.4088/PCC.10m00994gre.
［44］LORENZ T A，MESTON C M.Exercise improves sexual function in women taking antidepressants：results from a randomised crossover trial［J］．Depress Anxiety，2014，31（3）：188-195.
［45］ANDERSSON K E.Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction［J］．Pharmacol Rev，2011，63（4）：811-859．DOI：10.1124/pr.111.004515.
［46］MUSICKI B，LIU T，LAGODA G A，et al．Endothelial nitric oxide synthase regulation in female genital tract structures［J］．J Sex Med，2009，6 Suppl 3：247-253．DOI：10.1111/j.1743-6109.2008.01122.x.
［47］NURNBERG H G，SEIDMAN S N，GELENBERG A J，et al．Depression，antidepressant therapies，and erectile dysfunction：clinical trials of sildenafil citrate（Viagra）in treated and untreated patients with depression［J］．Urology，2002，60（2 Suppl 2）：58-66.
［48］KOPEYKINA I，KIM H J，KHATUN T，et al．Hypersexuality and couple relationships in bipolar disorder：a review［J］．J Affect Disord，2016，195：1-14．DOI：10.1016/j.jad.2016.01.035.
［49］RAJA M，AZZONI A.Sexual behavior and sexual problems among patients with severe chronic psychoses［J］．Eur Psychiatry，2003，18（2）：70-76.
［50］DOWNEY J，FRIEDMAN R C，HAASE E，et al．Comparison of sexual experience and behavior between bipolar outpatients and outpatients without mood disorders［J］．Psychiatry J，2016，2016：5839181．DOI：10.1155/2016/5839181.
［51］DELL'OSSO L，CARMASSI C，CARLINI M，et al．Sexual dysfunctions and suicidality in patients with bipolar disorder and unipolar depression［J］．J Sex Med，2009，6（11）：3063-3070．DOI：10.1111/j.1743-6109.2009.01455.x.
［52］CHEN L P，MURAD M H，PARAS M L，et al．Sexual abuse and lifetime diagnosis of psychiatric disorders：systematic review and meta-analysis［J］．Mayo Clin Proc，2010，85（7）：618-629．DOI：10.4065/mcp.2009.0583.
［53］ZUNCHEDDU C，CARPINIELLO B.Sexual dysfunctions and bipolar disorder：a study of patients submitted to a long-term lithium treatment［J］．Clin Ter，2006，157（5）：419-424.
［54］GHADIRIAN A M，ANANBle L，BéLANGER M C.Lithium，benzodiazepines，and sexual function in bipolar patients［J］．Am J Psychiatry，1992，149（6）：801-805．DOI：10.1176/ajp.149.6.801.
［55］YANG Y，WANG X.Sexual dysfunction related to antiepileptic drugs in patients with epilepsy［J］．Expert Opin Drug Saf，2016，15（1）：31-42．DOI：10.1517/14740338.2016.1112376.
［56］VERROTTI A，MENCARONI E，COFINI M，et al．Valproic acid metabolism and its consequences on sexual functions［J］．Curr Drug Metab，2016，17（6）：573-581.
［57］PAVONE C，GIACALONE N，VELLA M，et al．Relation between sexual dysfunctions and epilepsy，type of epilepsy，type of antiepileptic drugs：a prospective study［J］．Urologia，2017，84（2）：88-92．DOI：10.5301/uro.5000222.
［58］CALABRò R S，ITALIANO D，POLLICINO P，et al．Oxcarbazepine-related retrograde ejaculation［J］．Epilepsy Behav，2012，25（2）：174-175．DOI：10.1016/j.yebeh.2012.08.025.
［59］YOGARAJAH M，MULA M.Sexual dysfunction in epilepsy and the role of anti-epileptic drugs［J］．Curr Pharm Des，2017，23（37）：5649-5661．DOI：10.2174/1381612823666171004115230.
［60］SAROUKHANI S，EMAMI-PARSA M，MODABBERNIA A，et al．Aspirin for treatment of lithium-associated sexual dysfunction in men：randomized double-blind placebo-controlled study［J］．Bipolar Disord，2013，15（6）：650-656．DOI：10.1111/bdi.12108.
［61］LA TORRE A，GIUPPONI G，DUFFY D M，et al．Sexual dysfunction related to psychotropic drugs：a critical review.Part Ⅲ：mood stabilizers and anxiolytic drugs［J］．Pharmacopsychiatry，2014，47（1）：1-6．DOI：10.1055/s-0033-1358683.

[1]	ZHANG Siyu, ZHOU Yuqiu, DU Xiaohui, WANG Zhengjun. Advances in Duration of Untreated Psychosis and Its Early Intervention [J]. Chinese General Practice, 2023, 26(33): 4110-4117.
[2]	LI Qian, ZHANG Yunshu, YAN Baoping, WANG Jian, MA Yanjuan, WANG Yuan, QIN Yingjie, NA Long, REN Zhiyong, SUN Junwei, DENG Huaili, MA Hongjun, QU Xuehui, ZHOU Nan, SI Tianmei. Efficacy and Safety of Risperidone Microspheres for Injection (Ⅱ) in the Treatment of Patients with Acute Schizophrenia [J]. Chinese General Practice, 2023, 26(32): 4007-4012.
[3]	REN Yanfeng, LIU Shimeng, TAO Ying, CHEN Yingyao. A Systematic Review of Medication Preferences for Patients with Depression Based on Discrete Choice Experiment and Best-worst Scaling [J]. Chinese General Practice, 2023, 26(28): 3559-3564.
[4]	LIANG Xuemei, WANG Rui, ZHAO Yuhuan, XU Tianjiao, WANG Wei, SUN Weidong. Transcranial Low-level Laser Therapy: a Novel Treatment for Depression [J]. Chinese General Practice, 2023, 26(27): 3335-3341.
[5]	MA Rui, WANG Yu, LI Yuxin, WANG Zhengjun, ZHOU Yuqiu. Application of Cognitive Interviewing in the Development of a Help-seeking Motivation Scale for Patients with Schizophrenia [J]. Chinese General Practice, 2023, 26(23): 2907-2911.
[6]	SUN Yujing, ZHANG Jing, YU Hong, ZHOU Yuqiu, JIANG Wenlong, JIA Yannan. Effect of Childhood Trauma on Aggressive Behavior in Stable Schizophrenia Patients: the Chain Mediating Effect of Self-esteem and Resilience [J]. Chinese General Practice, 2023, 26(23): 2899-2906.
[7]	CAO Ziyao, QIAN Cheng, XIE Guohua, CHANG Qingsong, WU Donghui. Analysis on the Correlation of Passive Suicidal Ideation with Thyroid Stimulating Hormone and Prolactin among Elderly Schizophrenia Inpatients [J]. Chinese General Practice, 2023, 26(23): 2894-2898.
[8]	DING Jing, MENG Zhuocheng, ZHANG Yan, CUI Xiaohua, LIU Jiarui, HE Jiao, ZHANG Yang, LI Yajuan, YANG Liu. Retrospective Analysis of 2 992 Times of Therapeutic Drug Monitoring of Valproic Acid from 2019 to 2021 [J]. Chinese General Practice, 2023, 26(23): 2923-2929.
[9]	ZHA Qianqian, XU Lianying, CHEN Juan, HUANG Wen, ZHANG Xinqiong. Summary of Best Evidence for Prevention of Recurrence of Late-life Depression [J]. Chinese General Practice, 2023, 26(19): 2332-2338.
[10]	CAO Xiaolang, WANG Weiliang, YU Hong, WANG Xue, ZHOU Yuqiu. Application of Disability Point Matching Intervention Programme Based on Intervention Mapping Theory in Patients with Schizophrenia Disability [J]. Chinese General Practice, 2023, 26(19): 2376-2384,2394.
[11]	LIU Rui, DENG Jing, CHEN Ailing, CHENG Peihua, LUO Xingneng, HU Yongjiao, ZHANG Munan. Influence of Policy Factors on Healthcare-seeking Behaviors in Patients with Schizophrenia [J]. Chinese General Practice, 2023, 26(19): 2385-2394.
[12]	GE Anxin, ZHANG Guiqing, JIANG Liang, XING Wenlong, HU Min, LI Haohao, MENG Yao. Epidemiological Survey of the Prevalence and Associated Factors of Mental Disorders in Xinjiang Uygur Autonomous Region [J]. Chinese General Practice, 2023, 26(19): 2395-2401.
[13]	DU Yeming, ZHANG Yunqiao, WANG Zongqi, MIN Xue, CUI Yalian, WANG Yanfang. Characteristics of Somatic Symptoms and Their Correlations with Brain-derived Neurotrophic Factor and Inflammatory Cytokinesin Patients with Major Depressive Disorder [J]. Chinese General Practice, 2023, 26(12): 1463-1471.
[14]	SUN Liang, LIU Zhiwei, ZHANG Yulong, ZHANG Dapeng, LI Wenzheng, YAO Xianhu, LIU Huanzhong. Plasma Cytokine Level and Influencing Factors of Depression in Stable Schizophrenia Patients [J]. Chinese General Practice, 2023, 26(06): 687-691.
[15]	HU Shuwei, OU Wei, WANG Zhi, PENG Juan. Eye Movement Desensitization and Reprocessing versus Sertraline in the Treatment of Depressed Adolescents with Childhood Trauma [J]. Chinese General Practice, 2023, 26(06): 692-698.